News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

LipoScience, Inc. Begins Clinical Development of NMR-Based Cardiovascular Diagnostic Test for Novel Gut Flora Metabolite


4/26/2013 10:44:47 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care, today announced the start of the clinical development phase of a diagnostic test for cardiovascular disease based upon research demonstrating that a unique gut flora metabolite, trimethylamine-N-oxide (TMAO), is a predictor of cardiovascular risk.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES